Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 61

1.

Strategies for the discovery and development of therapies for metastatic breast cancer.

Eckhardt BL, Francis PA, Parker BS, Anderson RL.

Nat Rev Drug Discov. 2012 Jun 1;11(6):479-97. doi: 10.1038/nrd2372. Review.

PMID:
22653217
2.

Nanoparticle delivery for metastatic breast cancer.

Grobmyer SR, Zhou G, Gutwein LG, Iwakuma N, Sharma P, Hochwald SN.

Nanomedicine. 2012 Sep;8 Suppl 1:S21-30. doi: 10.1016/j.nano.2012.05.011. Epub 2012 May 26. Review.

PMID:
22640908
3.

Cost effectiveness of cytotoxic and targeted therapy for metastatic breast cancer: a critical and systematic review.

Blank PR, Dedes KJ, Szucs TD.

Pharmacoeconomics. 2010;28(8):629-47. doi: 10.2165/11535560-000000000-00000. Review.

PMID:
20524722
4.

On the development of models in mice of advanced visceral metastatic disease for anti-cancer drug testing.

Man S, Munoz R, Kerbel RS.

Cancer Metastasis Rev. 2007 Dec;26(3-4):737-47. Review.

PMID:
17846863
5.

Novel treatment options in the management of metastatic breast cancer.

Twelves C, Vahdat LT, Cortés J.

Clin Adv Hematol Oncol. 2011 May;9(5 Suppl 10):1-16. Review.

PMID:
21738118
6.

The prevention and management of distant metastases in women with breast cancer.

Glück S.

Cancer Invest. 2007 Feb;25(1):6-13. Review.

PMID:
17364551
7.

Breast cancer metastasis.

Scully OJ, Bay BH, Yip G, Yu Y.

Cancer Genomics Proteomics. 2012 Sep-Oct;9(5):311-20. Review.

PMID:
22990110
8.

Reappraising antiangiogenic therapy for breast cancer.

Kerbel RS.

Breast. 2011 Oct;20 Suppl 3:S56-60. doi: 10.1016/S0960-9776(11)70295-8. Review.

9.

From genetic abnormality to metastases: murine models of breast cancer and their use in the development of anticancer therapies.

Ottewell PD, Coleman RE, Holen I.

Breast Cancer Res Treat. 2006 Mar;96(2):101-13. Review.

PMID:
16319986
10.

Pro-metastatic tumor-stroma interactions in breast cancer.

Gangadhara S, Barrett-Lee P, Nicholson RI, Hiscox S.

Future Oncol. 2012 Nov;8(11):1427-42. doi: 10.2217/fon.12.134. Review.

PMID:
23148616
11.

Meaningful prevention of breast cancer metastasis: candidate therapeutics, preclinical validation, and clinical trial concerns.

Zimmer AS, Steeg PS.

J Mol Med (Berl). 2015 Jan;93(1):13-29. doi: 10.1007/s00109-014-1226-2. Epub 2014 Nov 22. Review.

PMID:
25412774
12.

Evaluation of the current knowledge limitations in breast cancer research: a gap analysis.

Thompson A, Brennan K, Cox A, Gee J, Harcourt D, Harris A, Harvie M, Holen I, Howell A, Nicholson R, Steel M, Streuli C.

Breast Cancer Res. 2008;10(2):R26. doi: 10.1186/bcr1983. Epub 2008 Mar 27. Review.

13.

Trastuzumab and lapatinib beyond trastuzumab progression for metastatic breast cancer: strategies and pitfalls.

Brandes AA, Franceschi E, Tosoni A, Degli Esposti R.

Expert Rev Anticancer Ther. 2010 Feb;10(2):179-84. doi: 10.1586/era.09.156. Review.

PMID:
20131994
14.

Preclinical recapitulation of antiangiogenic drug clinical efficacies using models of early or late stage breast cancer metastatis.

Kerbel RS, Guerin E, Francia G, Xu P, Lee CR, Ebos JM, Man S.

Breast. 2013 Aug;22 Suppl 2:S57-65. doi: 10.1016/j.breast.2013.07.011. Review.

PMID:
24074794
15.

Breast cancer and metastasis: on the way toward individualized therapy.

Trapé AP, Gonzalez-Angulo AM.

Cancer Genomics Proteomics. 2012 Sep-Oct;9(5):297-310. Review.

PMID:
22990109
16.

[Brain metastasis of breast tumors and blood brain barrier].

Diéras V, Pierga JY.

Bull Cancer. 2011 Apr;98(4):385-9. doi: 10.1684/bdc.2011.1336. Review. French.

17.

Emerging drugs in metastatic breast cancer.

Dizdar O, Altundag K.

Expert Opin Emerg Drugs. 2009 Mar;14(1):85-98. doi: 10.1517/14728210802625671 . Review.

PMID:
19278368
18.

Translating mathematical modeling of tumor growth patterns into novel therapeutic approaches for breast cancer.

Comen E, Morris PG, Norton L.

J Mammary Gland Biol Neoplasia. 2012 Dec;17(3-4):241-9. doi: 10.1007/s10911-012-9267-z. Epub 2012 Sep 26. Review.

PMID:
23011603
19.

New pharmacological strategies against metastatic spread.

Perret GY, Crépin M.

Fundam Clin Pharmacol. 2008 Oct;22(5):465-92. doi: 10.1111/j.1472-8206.2008.00614.x. Review.

PMID:
18844722
20.

Novel therapeutic approaches to the treatment of metastatic breast cancer.

Fernández Y, Cueva J, Palomo AG, Ramos M, de Juan A, Calvo L, García-Mata J, García-Teijido P, Peláez I, García-Estévez L.

Cancer Treat Rev. 2010 Feb;36(1):33-42. doi: 10.1016/j.ctrv.2009.10.001. Epub 2009 Nov 1. Review.

PMID:
19883980

Supplemental Content

Support Center